IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.92 Million USD | 17.05% |
| 2022 | -11.96 Million USD | -28.51% |
| 2021 | -9.31 Million USD | -12.93% |
| 2020 | -8.24 Million USD | 30.51% |
| 2019 | -11.86 Million USD | -17.4% |
| 2018 | -10.1 Million USD | -231.3% |
| 2017 | -3.05 Million USD | -158.56% |
| 2016 | -1.18 Million USD | -191.4% |
| 2015 | 1.29 Million USD | 173.94% |
| 2014 | -1.74 Million USD | -6.53% |
| 2013 | -1.63 Million USD | 27.16% |
| 2012 | -2.25 Million USD | 8.24% |
| 2011 | -2.45 Million USD | 20.8% |
| 2010 | -3.09 Million USD | -59.55% |
| 2009 | -1.94 Million USD | 30.86% |
| 2008 | -2.8 Million USD | -154.93% |
| 2007 | -1.1 Million USD | -40.93% |
| 2006 | -781.13 Thousand USD | -6922.71% |
| 2005 | -11.12 Thousand USD | -41.84% |
| 2004 | -7842.00 USD | -7161.11% |
| 2003 | -108.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.02 Million USD | -191.81% |
| 2023 Q2 | -2.86 Million USD | 11.3% |
| 2023 Q3 | -2.75 Million USD | 3.67% |
| 2023 FY | -9.92 Million USD | 17.05% |
| 2023 Q4 | -1.38 Million USD | 49.98% |
| 2023 Q1 | -3.22 Million USD | 60.77% |
| 2022 Q1 | -3.06 Million USD | -7.14% |
| 2022 FY | -11.96 Million USD | -28.51% |
| 2022 Q2 | -2.98 Million USD | 2.55% |
| 2022 Q3 | -2.67 Million USD | 10.32% |
| 2022 Q4 | -8.23 Million USD | -207.55% |
| 2021 Q1 | -2.26 Million USD | -77.06% |
| 2021 FY | -9.31 Million USD | -12.93% |
| 2021 Q2 | -2.19 Million USD | 3.1% |
| 2021 Q4 | -2.85 Million USD | -42.76% |
| 2021 Q3 | -2 Million USD | 8.63% |
| 2020 Q4 | -1.27 Million USD | 23.07% |
| 2020 Q3 | -1.66 Million USD | -0.61% |
| 2020 Q1 | -2.45 Million USD | 7.67% |
| 2020 FY | -8.24 Million USD | 30.51% |
| 2020 Q2 | -1.65 Million USD | 32.84% |
| 2019 Q1 | -2.58 Million USD | -3.56% |
| 2019 Q4 | -2.66 Million USD | 5.2% |
| 2019 Q3 | -2.8 Million USD | -7.8% |
| 2019 Q2 | -2.6 Million USD | -0.62% |
| 2019 FY | -11.86 Million USD | -17.4% |
| 2018 Q3 | -2.94 Million USD | -22.62% |
| 2018 Q2 | -2.4 Million USD | -6.05% |
| 2018 Q1 | -2.26 Million USD | -107.52% |
| 2018 FY | -10.1 Million USD | -231.3% |
| 2018 Q4 | -2.49 Million USD | 15.12% |
| 2017 Q4 | -1.09 Million USD | -39.51% |
| 2017 FY | -3.05 Million USD | -158.56% |
| 2017 Q3 | -782 Thousand USD | -17.42% |
| 2017 Q2 | -666 Thousand USD | -30.08% |
| 2017 Q1 | -512 Thousand USD | -236.17% |
| 2016 Q2 | -840 Thousand USD | -12.6% |
| 2016 Q4 | 376 Thousand USD | 1153.33% |
| 2016 FY | -1.18 Million USD | -191.4% |
| 2016 Q3 | 30 Thousand USD | 103.57% |
| 2016 Q1 | -746 Thousand USD | -379.4% |
| 2015 FY | 1.29 Million USD | 173.94% |
| 2015 Q4 | 267 Thousand USD | -80.25% |
| 2015 Q2 | -275 Thousand USD | -409.26% |
| 2015 Q1 | -54 Thousand USD | 78.91% |
| 2015 Q3 | 1.35 Million USD | 591.64% |
| 2014 Q2 | -614 Thousand USD | -38.91% |
| 2014 FY | -1.74 Million USD | -6.53% |
| 2014 Q4 | -256 Thousand USD | 41.01% |
| 2014 Q3 | -434 Thousand USD | 29.32% |
| 2014 Q1 | -442 Thousand USD | 31.37% |
| 2013 Q4 | -644 Thousand USD | -7.51% |
| 2013 FY | -1.63 Million USD | 27.16% |
| 2013 Q3 | -599 Thousand USD | -765.56% |
| 2013 Q2 | 90 Thousand USD | 118.52% |
| 2013 Q1 | -486 Thousand USD | -43.79% |
| 2012 Q3 | -698 Thousand USD | -10.79% |
| 2012 Q4 | -338 Thousand USD | 51.58% |
| 2012 FY | -2.25 Million USD | 8.24% |
| 2012 Q1 | -582 Thousand USD | 20.6% |
| 2012 Q2 | -630 Thousand USD | -8.25% |
| 2011 Q1 | -600 Thousand USD | 41.06% |
| 2011 Q2 | -580 Thousand USD | 3.33% |
| 2011 Q4 | -733 Thousand USD | -35.99% |
| 2011 Q3 | -539 Thousand USD | 7.07% |
| 2011 FY | -2.45 Million USD | 20.8% |
| 2010 Q2 | -943 Thousand USD | -22.15% |
| 2010 Q1 | -772 Thousand USD | -34.05% |
| 2010 FY | -3.09 Million USD | -59.55% |
| 2010 Q3 | -363 Thousand USD | 61.51% |
| 2010 Q4 | -1.01 Million USD | -180.44% |
| 2009 Q2 | -115.8 Thousand USD | 80.47% |
| 2009 Q3 | -655.8 Thousand USD | -466.32% |
| 2009 Q1 | -592.9 Thousand USD | -68.32% |
| 2009 FY | -1.94 Million USD | 30.86% |
| 2009 Q4 | -575.9 Thousand USD | 12.18% |
| 2008 Q4 | -352.24 Thousand USD | 58.03% |
| 2008 Q1 | -463.42 Thousand USD | -28.8% |
| 2008 Q2 | -1.15 Million USD | -148.48% |
| 2008 Q3 | -839.21 Thousand USD | 27.12% |
| 2008 FY | -2.8 Million USD | -154.93% |
| 2007 Q2 | -35.88 Thousand USD | 74.34% |
| 2007 Q3 | -533.48 Thousand USD | -1386.72% |
| 2007 Q4 | -359.79 Thousand USD | 32.56% |
| 2007 FY | -1.1 Million USD | -40.93% |
| 2007 Q1 | -139.84 Thousand USD | 65.41% |
| 2006 Q3 | -249.27 Thousand USD | -119.93% |
| 2006 Q4 | -404.28 Thousand USD | -62.18% |
| 2006 FY | -781.13 Thousand USD | -6922.71% |
| 2006 Q1 | -1648.00 USD | 44.36% |
| 2006 Q2 | -113.34 Thousand USD | -6777.73% |
| 2005 Q1 | -3751.00 USD | -84.51% |
| 2005 Q3 | -2229.00 USD | -2.2% |
| 2005 FY | -11.12 Thousand USD | -41.84% |
| 2005 Q4 | -2962.00 USD | -32.88% |
| 2005 Q2 | -2181.00 USD | 41.86% |
| 2004 Q3 | -2746.00 USD | 10.35% |
| 2004 Q4 | -2033.00 USD | 25.97% |
| 2004 FY | -7842.00 USD | -7161.11% |
| 2004 Q2 | -3063.00 USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | -108.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HST Global, Inc. | -146.21 Thousand USD | -6689.549% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1069.9% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -16324.388% |
| CytoDyn Inc. | -49.84 Million USD | 80.083% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 80.796% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -380.07 USD | -2611787.284% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -515.537% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -42.163% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -66186.058% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -2149.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -13.77 Million USD | 27.922% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 84.142% |
| SQZ Biotechnologies Company | -79.46 Million USD | 87.508% |
| Resverlogix Corp. | -3.61 Million USD | -174.986% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1469.717% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 8.858% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -139.439% |
| Mesoblast Limited | -87.95 Million USD | 88.714% |
| GB Sciences, Inc. | -1.36 Million USD | -629.028% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1069.9% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 118.738% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -228.042% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -25.609% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -213.013% |
| ContraFect Corporation | -65.15 Million USD | 84.764% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -23.169% |
| BioStem Technologies, Inc. | -8.48 Million USD | -17.023% |
| LadRx Corporation | 400.44 Thousand USD | 2579.005% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 37.454% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -494.787% |
| CSL Limited | 2.64 Billion USD | 100.376% |
| Biomind Labs Inc. | -1.21 Million USD | -717.495% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -167.557% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 115.241% |
| Nascent Biotech, Inc. | -2.08 Million USD | -375.503% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 86.757% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -50.955% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -165.926% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -445.281% |
| Marizyme, Inc. | -65.34 Million USD | 84.809% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -12.246% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -954.349% |
| Zenith Capital Corp. | -10.59 Million USD | 6.314% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -243.211% |
| Halberd Corporation | -79.67 Thousand USD | -12359.21% |
| Genus plc | 7.9 Million USD | 225.658% |
| Pharming Group N.V. | -10.54 Million USD | 5.887% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -357.505% |
| IMV Inc. | -36.48 Million USD | 72.792% |
| Affymax, Inc. | -14.42 Million USD | 31.177% |
| SYBLEU INC | -180.3 Thousand USD | -5405.701% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 10229.592% |
| Enzolytics Inc. | -2.17 Million USD | -356.03% |
| argenx SE | -295.05 Million USD | 96.636% |
| AVAX Technologies, Inc. | -6.41 Million USD | -54.779% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -474.66% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -643.356% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -164.973% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -12460.576% |
| Cell Source, Inc. | -5.32 Million USD | -86.555% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -683.421% |
| Q BioMed Inc. | -2.05 Million USD | -383.75% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -123.454% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -159.937% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -316.948% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -103.17% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 83.379% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -220.043% |
| Rebus Holdings, Inc. | -1.02 Million USD | -873.235% |
| Helix BioMedix, Inc. | -1.05 Million USD | -840.006% |
| Skye Bioscience, Inc. | -37.64 Million USD | 73.63% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -409.273% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -395.084% |
| ONE Bio Corp. | 8.67 Million USD | 214.411% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -70.648% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -465.715% |
| Agentix Corp. | -1.37 Million USD | -622.378% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 243.359% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -149.862% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -42611.471% |
| Kadimastem Ltd | -3.3 Million USD | -200.145% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3530.917% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2289.29% |
| NovAccess Global Inc. | -4.76 Million USD | -108.149% |
| Itoco Inc. | -1.86 Million USD | -431.141% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -4251.523% |
| Qrons Inc. | -789.34 Thousand USD | -1157.622% |
| Mobile Lads Corp. | -2.26 Million USD | -338.609% |
| Genscript Biotech Corporation | -95.47 Million USD | 89.603% |
| International Stem Cell Corporation | -131 Thousand USD | -7477.863% |
| Bioxytran, Inc. | -4.28 Million USD | -131.939% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -18191.2% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -292.333% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 79.35% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -369.584% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1171.247% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -213.352% |
| Neutra Corp. | -233.46 Thousand USD | -4152.029% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 51.077% |
| PureTech Health plc | -65.69 Million USD | 84.89% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 53.321% |
| IXICO plc | -1.17 Million USD | -742.699% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 82.623% |
| CSL Limited | 2.64 Billion USD | 100.376% |
| Cellectis S.A. | -103.17 Million USD | 90.378% |